Every public signal F4 has attached to this firm, with sources and cross-entity links.
3 investments· JUN 2026Show all
Investment
HTH VC (Zambon Group) participated in a $5M Series A round for Leuko, a digital health startup developing non-invasive white blood cell monitoring for cancer patients.
HTH participated as a co-investor in a VC round for Lys Therapeutics in June 2026. Lys Therapeutics is a French biotech developing first-in-class monoclonal antibody LYS241 for neurovascular and neurodegenerative diseases.